You have read all your free articles, to continue reading subscribe to read the rest of this content.
Depomed, Inc. has closed the acquisition of the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals, Inc. for $1.05 billion. The NUCYNTA franchise includes NUCYNTA® ER (tapentadol) extended release tablets indicated for the management of pain, including neuropathic pain associated Already a subscriber Login You have read all your free articles, to…
Cadila Pharmaceuticals Sweden AB has announced the acquisition of Swedish BioChromix NewCo. BioChromix NewCo was founded in 2013, based the technology previously developed by BioChromix AB and BioChromix Pharma AB, to explore a class of conjugated heteocyclic compounds for the treatment of proteiAlready a subscriber Login You have read all…
Isofol, a clinical stage pharmaceutical company based in Gothenburg, Sweden, has launched a global program to identify one or more strategic partners for commercialization of its Modufolin(R) chemotherapy asset. The Sage Group, which is based in Europe, the USA and Asia, has been appointed by IAlready a subscriber Login You…
Swedish Orphan Biovitrum (Sobi) has announced a definitive agreement to acquire Dova Pharmaceuticals by means of a tender offer. The transaction is valued at up to USD 915 million on a fully diluted basis The consideration consists of an upfront payment of USD 27.50 per share in cash and, one…
